About Mesenteric estrogen-dependent adipogenesis protein
Mesenteric estrogen-dependent adipogenesis protein (MEDAG) is a protein
from Homo sapiens identified by UniProt accession
Q5VYS4, 303 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Mesenteric estrogen-dependent adipogenesis protein |
|---|
| UniProt accession | Q5VYS4 |
|---|
| Gene | MEDAG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 303 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (43)
Diseases linked to this target (Open Targets).
- 3-hydroxypropylmercapturic acid measurement · score 0.31
- protein measurement · score 0.26
- gut microbiome measurement · score 0.12
- breast cancer · score 0.09
- mathematical ability · score 0.07
- type 2 diabetes mellitus · score 0.05
- cognitive function measurement · score 0.05
- self reported educational attainment · score 0.04
- breast carcinoma · score 0.04
- colorectal adenocarcinoma · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5VYS4-F1 | alphafold | PREDICTED | 74.47 | — |
Amino-acid sequence (303 residues)
MAGAACEPVA RPSLTSISSG ELRSLWTCDC ELALLPLAQL LRLQPGAFQL SGDQLVVARP GEPAAARGGF NVFGDGLVRL DGQLYRLSSY IKRYVELTNY CDYKDYRETI LSKPMLFFIN VQTKKDTSKE RTYAFLVNTR HPKIRRQIEQ GMDMVISSVI GESYRLQFDF QEAVKNFFPP GNEVVNGENL SFAYEFKADA LFDFFYWFGL SNSVVKVNGK VLNLSSTSPE KKETIKLFLE KMSEPLIRRS SFSDRKFSVT SRGSIDDVFN CNLSPRSSLT EPLLAELPFP SVLESEETPN QFI
Explore Mesenteric estrogen-dependent adipogenesis protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets